U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H23NO4.ClH
Molecular Weight 377.862
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THEBACON HYDROCHLORIDE

SMILES

Cl.COC1=CC=C2C[C@@H]3[C@@H]4CC=C(OC(C)=O)[C@@H]5OC1=C2[C@]45CCN3C

InChI

InChIKey=OTQDEDKVELDPIY-ZKVYEUBZSA-N
InChI=1S/C20H23NO4.ClH/c1-11(22)24-16-7-5-13-14-10-12-4-6-15(23-3)18-17(12)20(13,19(16)25-18)8-9-21(14)2;/h4,6-7,13-14,19H,5,8-10H2,1-3H3;1H/t13-,14+,19-,20-;/m0./s1

HIDE SMILES / InChI

Description

Thebacon (dihydrocodeinone enol acetate, trade name Acedicon) is semisynthetic opioid analgetic and antitussive compound. Boehringer-Ingelheim merketed Acedicon for the treatment of cough. Thebacon is a Schedule I drug, that has not got approved use in US.

CNS Activity

CNS Active
4,002

Originator

Boehringer Ingelheim
130

Approval Year

Unknown
149,124

Targets

Primary TargetPharmacologyConditionPotency
Carboxylesterase 2
9
Substrate
661

Conditions

ConditionModalityTargetsHighest PhaseProduct
Cough
106
 Primary
Approved
8,583
ACEDICON

PubMed

Patents

US1731152
2

Sample Use Guides

In Vivo Use Guide
7.5-15 mg per day
Route of Administration: Other
In Vitro Use Guide
Unknown
ACTIVE MOIETY
Structure of THEBACON
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966